Approval based on INAVO120 data showing the Itovebi™ (inavolisib)-based regimen more than doubled progression-free survival ...

Fulvestrant reduced risk of progression by 20% and extended median progression-free survival beyond anastrozole October 08, 2016 08:00 AM Eastern Daylight Time ...

But for those taking fulvestrant and a placebo, cancer returned in an average of five months, the study found. Side effects were more common in the group taking the new drug combo, however.

The Food and Drug Administration (FDA) has approved Truqap ™ (capivasertib) in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal ...

For fulvestrant to work well, the cells must also be responsive to estrogen, and producing the estrogen receptor ER-alpha. ER-alpha's importance to fulvestrant's anti-estrogenic action had been ...

Fulvestrant in combination with everolimus extended PFS significantly longer than fulvestrant with vistusertib or fulvestrant alone among women with hormone receptor-positive metastatic breast ...

References: Capivasertib in combination with Faslodex ® (fulvestrant) granted Priority Review in the US for patients with advanced HR-positive breast cancer. News release. June 12, 2023. https ...

Fulvestrant was as effective as anastrozole in terms of time to progression (TTP) (hazard ratio, 0.92; 95% confidence interval [CI], 0.74-1.14; P =.43). Median TTP was 5.4 months with fulvestrant ...

The CONFIRM trial was an international multicentre double-blind parallel-group randomised controlled trial (RCT) that included 736 patients who had previously received an anti-oestrogen or an ...

The addition of dalpiciclib to fulvestrant appeared effective and safe for certain patients with advanced breast cancer, according to randomized phase 3 study results presented during the virtual ...

Fulvestrant is not a cost-effective use of NHS resources compared with aromatase inhibitors 3.12 The committee noted that the overall-survival projection for fulvestrant was mostly based on data from ...

Correspondence Anastrozole and Fulvestrant in Metastatic Breast Cancer Published October 25, 2012 N Engl J Med 2012;367: 1662 - 1664 DOI: 10.1056/NEJMc1210463 ...